ARLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), (“KALA” or the “Company”) today announced the successful completion of its loan settlement with Oxford Finance, LLC ...
ARLINGTON, Mass., May 23, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of ...
Shares of Kala Pharmaceuticals surged Wednesday after the small biotechnology company announced a drug candidate for a rare eye disease. The Food and Drug Administration has accepted Kala's ...
Alcon has expanded its portfolio of eye disease products by paying $60 million upfront for the rights to two commercial products based on mucus-penetrating particle drug delivery technology. The sale ...
・A rescue financing and loan settlement halted an impending asset seizure after Oxford’s default. ・A two-stage preferred stock deal supplies up to $6 million to stabilize operations and restructure ...
ARLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback